U.S. markets closed

  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     

  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     

  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     

  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     

  • Crude Oil

    73.81
    +0.19 (+0.26%)
     

  • Gold

    1,816.90
    -18.90 (-1.03%)
     

  • Silver

    25.55
    -0.23 (-0.90%)
     

  • EUR/USD

    1.1871
    -0.0025 (-0.21%)
     

  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     

  • GBP/USD

    1.3906
    -0.0051 (-0.37%)
     

  • USD/JPY

    109.6150
    +0.1540 (+0.14%)
     

  • BTC-USD

    40,881.39
    +1,200.23 (+3.02%)
     

  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     

  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     

  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders

Vandana Singh
·1 min read

  • Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody.

  • The results will be presented at the American Society of Gene and Cell Therapy.

  • Data demonstrate durable expression in the central nervous system (CNS). They may represent a new single-dose therapeutic strategy for treating various tauopathies such as progressive supranuclear palsy, frontal, temporal dementia, and Alzheimer's disease.

  • Voyager has developed modular antibody vectorization cassettes consisting of an adeno-associated virus (AAV) vector and a transgene encoding anti-tau monoclonal full-length antibodies.

  • Following intravenous administration and transduction of target cells in the brain, the expressed antibodies are functionally reconstituted and subsequentially secreted into the parenchyma.

  • Anti-tau antibody expression was detected as early as two days post-dose, reaching maximum levels at day 7, with durable expression extending to 28 days.

  • Dose-dependent decreases in the levels of pathological tau and neurofibrillary tangles were observed, resulting in up to 59% reduction in tau pathology.

  • Price Action: VYGR shares are trading 2.5% higher at $4.51 on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday

    A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

  • My girlfriend cosigned my mortgage. I paid the mortgage for 4 years, plus a $125,000 down payment. She paid the utilities. Now she wants half

    ‘I couldn’t secure the loan on my own until the other house was sold. So I applied for the mortgage with my girlfriend.’

  • Why Nio Stock Popped Friday

    Many different U.S.-listed Chinese technology stocks have been hit in recent days by fear and uncertainty related to a crackdown by the Chinese government. The battle took another turn today, but there's reason to think Chinese electric vehicle (EV) maker Nio (NYSE: NIO) might benefit. As of 3:20 p.m., Nio shares were up 4% on the day, after having jumped more than 6% earlier.

  • Why Skyworks Solutions Stock Crashed 9% After Beating Earnings

    Pity the shareholders of Skyworks Solutions (NASDAQ: SWKS) -- they just can't catch a break. Skyworks, which was expected to earn $2.14 per share on $1.1 billion in third-quarter sales, last night reported EPS of $2.15 on sales of $1.12 billion. It was a small beat, but it was a beat -- yet Skyworks stock was still down 8.6% at noon today.

  • Why Atlassian Stock Jumped 31% Friday Morning

    The company behind the popular business collaboration platform Jira delivered another strong earnings surprise in the fourth quarter.

  • Why Shares of Dexcom Are Gaining This Morning

    What happened Shares of continuous glucose monitor (CGM) maker Dexcom (NASDAQ: DXCM) are up more than 9% this morning after reporting sales and earnings that beat analyst estimates. Management also increased its full-year guidance for both metrics.

  • Here's Why AMD's Acquisition of Xilinx Is Such a Great Deal

    Xilinx will substantially boost AMD's profile in the chip space and make it even more profitable.

  • Forget Amazon, These 2 Nasdaq Highfliers Are Skyrocketing Friday

    The stock market gave back some of its recent gains on Friday, as high-profile earnings reports weighed on parts of the market. In particular, declines for the Nasdaq Composite (NASDAQINDEX: ^IXIC) were worse than most other stock indexes, with the Nasdaq down more than 0.6% as of 12:30 p.m. EDT. Many investors were displeased with a downbeat outlook from e-commerce giant Amazon (NASDAQ: AMZN), whose shares fell precipitously.

  • 6 Social Security Changes for 2021

    Every October, the Social Security Administration (SSA) announces its annual changes to the Social Security program for the coming year. Below is our analysis of the Social Security changes that were announced in Oct. 2020 to take effect on Jan. 1, 2021, according to the SSA's annual fact sheet. Keep them in mind when you update your Social Security information. For 2021, nearly 70 million Social Security recipients are seeing a 1.3% cost-of-living adjustment (COLA) to their monthly benefits. The adjustment helps benefits keep pace with inflation and is based on the Consumer Price Index for Urban Wage Earners and Clerical Workers (CPI-W) as calculated by the Bureau of Labor Statistics (BLS).

  • SEC freezes Chinese company IPOs over risk disclosures: report

    U.S.-listed Chinese companies traded lower in early trading on Friday on a Reuters report that the U.S. Securities and Exchange Commission (SEC) has stopped processing registrations of U.S. initial public offerings (IPOs) and other sales of securities by Chinese companies.

  • Pinterest stock drops after mixed Q2 earnings results

    Yahoo Finance's Emily McCormick breaks down the key numbers from Pinterest's Q2 earnings report. 

  • ReconAfrica Commences the Kavango Basin's First 2D Seismic Program & Launch a Comprehensive Community Water Well Drilling Campaign, NE Namibia

    Reconnaissance Energy Africa Ltd. (the "Company" or "ReconAfrica") (TSXV: RECO) (OTCQX: RECAF) (Frankfurt: 0XD) is pleased to announce initiation of the 450km 2D seismic program and a comprehensive community water well drilling campaign in the Kavango basin of NE Namibia.

  • 15 Best High Volume Stocks to Buy Now

    In this article, we discuss the 15 best high volume stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best High Volume Stocks to Buy Now. In May this year, the chief of the United States Securities and Exchange Commission Chair Gary Gensler appeared […]

  • My Top Cloud Computing Stock to Buy Right Now

    Enterprises are moving resources to the cloud, and it's easy to see why. Cloud computing makes it possible to access services like computing, storage, and networking through the internet. Traditionally, enterprise applications were delivered from private data centers, and they were run on a small number of servers.

  • Boeing Scrubs Its Space Capsule Launch. Blame the Russians.

    Otherworldly investors will have to wait a little longer for the next dramatic step in commercial space travel.

  • Amazon revenue disappoints, Pinterest falls on user growth, P&G’s new CEO

    Brian Sozzi, Julie Hyman, and Myles Udland break down earnings which include: Amazon missing revenue estimates, Pinterest shares falling after reporting a significant decline in monthly users in Q2, and Procter & Gamble announcing a new CEO. 

  • 15 Most Valuable Biotech Companies in the World

    In this article we will take a look at the 15 most valuable biotech companies in the world. You can skip our detailed analysis of the biotechnology industry’s outlook for 2021, and some of the major growth catalysts for biotech stocks, and go directly to the 5 Most Valuable Biotech Companies in the World. Mankind […]

  • VALE SA (VALE) Q2 2021 Earnings Call Transcript

    With us today are Mr. Eduardo de Salles Bartolomeo, Chief Executive Officer; Mr. Luciano Siani Pires, Executive Vice President, Finance and Investor Relations; Mr. Marcello Spinelli, Executive Vice President, Iron Ore; Mr. Mark Travers, Executive Vice President, Base Metals; Mr. Carlos Medeiros, Executive Vice President, Safety and Operational Excellence; and Mr. Alexandre D'Ambrosio, Executive Vice President, Legal and Tech. First, Mr. Eduardo Bartolomeo will proceed to the presentation on Vale's second quarter 2021 performance.

  • Is There Any Hope Left for Axsome Therapeutics?

    Axsome Therapeutics (NASDAQ: AXSM) has been a zero-to-hero biotech stock. It's still a company with a lot of potential, though -- it has four leading treatment candidates in its pipeline, all with high chances of earning regulatory approval. It announced top-line clinical trial results on AXS-05 for the treatment of depression (phase 2), AXS-07 for the treatment of migraine headaches (phase 3), and AXS-12 for the treatment of narcolepsy (phase 2).

  • 15 Stocks that Will Double In 2021

    In this article, we discuss the 15 stocks that will double in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks that Will Double In 2021. The economy of 2020 was closely linked to the COVID-19 pandemic. However, the vaccine rollout at the turn of the […]